AUBURN, WASHINGTON — Syntrix Pharmaceuticals is pleased to announce that it has been invited to present development and financing goals at the upcoming 25th Life Sciences Innovation Northwest (LSINW) conference on April 23-24.
John Zebala, MD, PhD, co-founder and CEO will provide an update on SX-682, the novel first-in-class oral dual CXCR1/2 inhibitor targeting immunosuppressive myeloid cells in the tumor microenvironment. SX-682 has achieved positive safety and efficacy results in metastatic melanoma and myelodysplastic syndromes. SX-682 is also other proof-of-concept trials in other oncology indications.
About SX-682
SX-682 is an oral allosteric small-molecule inhibitor of CXCR1 and CXCR2 (CXCR1/2) being investigated in several Phase 1/2 clinical trials. CXCR1/2 is a signaling pathway that acts as a “master switch” in the tumor microenvironment. It is involved in the recruitment of immunosuppressive MDSCs and autocrine growth of disease-initiating leukemic stem cells in AML and myelodysplastic syndromes (MDS). CXCR2 overexpression is predictive of transfusion dependence in MDS. CXCR2 inhibition reduces proliferation of leukemic cell lines and primary MDS/AML patient samples in vitro. SX-682 has been validated in major solid tumor models, where it exhibits mono-agent activity, blocks metastasis, depletes MDSCs, activates infiltration and killing by immune effector cells, reverses chemo-resistance, and enhances immune-checkpoint blockade. More information about clinical trials with SX-682 is available at https://clinicaltrials.gov/search?intr=SX-682.
About Syntrix
Syntrix is a pharmaceutical company committed to discovering and delivering innovative therapies to solve the most difficult clinical problems. Convergent Science & Strategy. Breakthrough Medicines.
Disclosure Notice
This release contains forward-looking information that is based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances. Actual results may vary from what is projected. Syntrix does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact: Aaron Schuler, PhD, 253-833-8009, x21
